Tango Therapeutics, Inc. (TNGX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
100 Binney Street
Boston, MA 02142
United States of America (the)
Phone
857 320 4900
Website
Sector
Healthcare
Industry
Biotechnology
Employees
155
First IPO Date
September 03, 2020
| Name | Title | Pay | Year Born |
| Malte Peters | President, Chief Executive Officer & Director | 148,315 | 1962 |
| Matthew Gall | Chief Financial Officer | 717,616 | 1977 |
| Daniella Beckman | Executive Officer | 765,152 | 1979 |
| Adam S. Crystal | President of Research & Development | 928,209 | 1977 |
| Barbara L. Weber | Founder & Executive Chair | 1.24M | 1957 |
| Jannik N. Andersen | Chief Scientific Officer | 0 | N/A |
| Elizabeth Pingpank Hickin | Vice President of IR & Corporate Communications | 0 | N/A |
| Julie Carretero | Chief Human Resources Officer | 0 | 1973 |
| Julie Fogarty | Vice President of Legal & Corporate Secretary | 0 | N/A |
| Michael Palmieri | Chief Technical Operations Officer | 0 | N/A |
| Philippe Serrano | Chief Regulatory Officer | 0 | N/A |
| Antoni Ribas | Founder & Member of Scientific Advisory Board | 0 | 1967 |
| William G. Kaelin Jr. | Founder & Member of Scientific Advisory Board | 0 | 1958 |
| Alan Ashworth | Founder & Member of Scientific Advisory Board | 0 | 1961 |
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.